STUB1 and myocardial infarction: For instance, it has been reported that CHIP carriers have significantly higher levels of C-reactive protein compared to non-carriers, even in the subgroup of patients with known CVD.132 Using samples from the CANTOS trial that evaluated the effect of canakinumab in patients with atherosclerotic disease after myocardial infarction and high levels of C-reactive protein,16 it was shown that IL-1β neutralization with canakinumab may be more beneficial for patients with CHIP associated with TET2 mutations, compared to non-carriers of CHIP-associated mutations.133